219580-11-7 | Pd173074

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$17.00	$12.00
2mg	98%	in stock	$23.00	$17.00
5mg	98%	in stock	$38.00	$27.00
10mg	98%	in stock	$52.00	$36.00
25mg	98%	in stock	$107.00	$75.00
50mg	98%	in stock	$145.00	$102.00
100mg	98%	in stock	$228.00	$160.00
250mg	98%	in stock	$460.00	$322.00
1g	98%	in stock	$1,463.00	$1,024.00

Description

• Catalog Number: AF31547
• Chemical Name: Pd173074
• CAS Number: 219580-11-7
• Molecular Formula: C28H41N7O3
• Molecular Weight: 523.6702
• MDL Number: MFCD08705327
• SMILES: CCN(CCCCNc1ncc2c(n1)nc(c(c2)c1cc(OC)cc(c1)OC)NC(=O)NC(C)(C)C)CC

Computed Properties

• Complexity: 690
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 38
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 13
• XLogP3: 4.5

Literature

• Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.

  Lung cancer (Amsterdam, Netherlands) 20161101

• Osmotic Induction of Angiogenic Growth Factor Expression in Human Retinal Pigment Epithelial Cells.

  PloS one 20160101

• Deletion of the PH-domain and Leucine-rich Repeat Protein Phosphatase 1 (Phlpp1) Increases Fibroblast Growth Factor (Fgf) 18 Expression and Promotes Chondrocyte Proliferation.

  The Journal of biological chemistry 20150626

• FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway.

  The Journal of biological chemistry 20140117

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.

  Bioorganic & medicinal chemistry letters 20121201

• Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20121101

• Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.

  The Journal of biological chemistry 20121026

• Transforming fusions of FGFR and TACC genes in human glioblastoma.

  Science (New York, N.Y.) 20120907

• FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120715

• Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

  Nature medicine 20120701

• Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.

  British journal of cancer 20120410

• Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.

  Phytotherapy research : PTR 20120101

• FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation.

  Journal of bone and mineral metabolism 20120101

• Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.

  Journal of biochemistry 20120101

• Activation of glial FGFRs is essential in glial migration, proliferation, and survival and in glia-neuron signaling during olfactory system development.

  PloS one 20120101

• Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.

  Leukemia research 20110901

• FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110815

• MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.

  Oncogene 20110811

• Protein kinase C delta mediates fibroblast growth factor-2-induced interferon-tau expression in bovine trophoblast.

  Biology of reproduction 20110501

• Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

  British journal of cancer 20110104

• Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.

  Proceedings of the National Academy of Sciences of the United States of America 20101214

• Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.

  Growth factors (Chur, Switzerland) 20100801

• Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation.

  Development (Cambridge, England) 20100315

• 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.

  The Journal of pharmacology and experimental therapeutics 20100301

• Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling.

  Journal of neuro-oncology 20090901

• Synthesis of 4-substituted pyrido[2,3-d]pyrimidin-4(1H)-one as analgesic and anti-inflammatory agents.

  Bioorganic & medicinal chemistry letters 20090701

• Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes.

  American journal of physiology. Endocrinology and metabolism 20090101

• Expression profiles of protein tyrosine kinase genes in human embryonic stem cells.

  Reproduction (Cambridge, England) 20081001

• Fibroblast growth factor-regulated palmitoylation of the neural cell adhesion molecule determines neuronal morphogenesis.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20080903

• FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

  Cancer research 20080401

• An efficient synthesis of pyrido[2,3-d]pyrimidine derivatives and related compounds under ultrasound irradiation without catalyst.

  Ultrasonics sonochemistry 20080301

• Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.

  Clinical & experimental metastasis 20080101

• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

  Proceedings of the National Academy of Sciences of the United States of America 20071218

• Activin A is an anticatabolic autocrine cytokine in articular cartilage whose production is controlled by fibroblast growth factor 2 and NF-kappaB.

  Arthritis and rheumatism 20071101

• Novel inhibitor for fibroblast growth factor receptor tyrosine kinase.

  Bioorganic & medicinal chemistry letters 20070901

• Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

  Neoplasia (New York, N.Y.) 20070201

• Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.

  Molecular endocrinology (Baltimore, Md.) 20061101

• A model for the pharmacological treatment of crouzon syndrome.

  Neurosurgery 20060701

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation.

  Analytical chemistry 20060201

• Guanosine analog in the pyrido[2,3-d]pyrimidine ring system as a potential toll-like receptor agonist.

  Nucleosides, nucleotides & nucleic acids 20060101

• Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.

  Journal of medicinal chemistry 20050714

• Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.

  Nuclear medicine and biology 20050501

• Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

  Endocrinology 20050301

• Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050201

• Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation.

  The Journal of biological chemistry 20041126

• [An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes].

  Deutsche medizinische Wochenschrift (1946) 20041001

• Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.

  Leukemia 20040501

• Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.

  Oncogene 20040429

• Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells.

  Journal of neuroscience research 20031115

• A one-pot microwave-assisted synthesis of pyrido[2,3-d]pyrimidines.

  Molecular diversity 20030101

• Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.

  Acta crystallographica. Section D, Biological crystallography 20020901

• Pyridopyrimidine analogues as novel adenosine kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20010820